Replimune Group Files 8-K on Operations

Ticker: REPL · Form: 8-K · Filed: 2025-05-22T00:00:00.000Z

Sentiment: neutral

Topics: operations, financial-condition, filing

TL;DR

Replimune Group filed an 8-K on May 22, 2025, updating investors on its financial and operational status.

AI Summary

Replimune Group, Inc. filed an 8-K on May 22, 2025, reporting on its results of operations and financial condition. The filing details financial statements and exhibits related to the company's business operations. No specific financial figures or events were detailed in the provided text excerpt.

Why It Matters

This filing provides an update on Replimune Group's financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting operational and financial information, with no immediate indication of significant risk events.

Key Players & Entities

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided text excerpt indicates the filing pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not specify the actual financial figures or operational details.

What is the exact date of the earliest event reported in this 8-K?

The exact date of the earliest event reported is May 22, 2025.

What is Replimune Group, Inc.'s Commission File Number?

Replimune Group, Inc.'s Commission File Number is 001-38596.

Where are Replimune Group, Inc.'s principal executive offices located?

Replimune Group, Inc.'s principal executive offices are located at 500 Unicorn Park Drive Suite 303, Woburn, MA 01801.

What is the purpose of filing a Form 8-K?

A Form 8-K is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 to announce major corporate events that shareholders should know about.

From the Filing

0001104659-25-051847.txt : 20250522 0001104659-25-051847.hdr.sgml : 20250522 20250522080553 ACCESSION NUMBER: 0001104659-25-051847 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250522 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 25974767 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 tm2515645d2_8k.htm FORM 8-K false 0001737953 0001737953 2025-05-22 2025-05-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  May 22, 2025       REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38596   82-2082553 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)   500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (Address of principal executive offices, including Zip Code)   Registrant’s telephone number, including area code: ( 781 ) 222-9600   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   REPL   The Nasdaq Stock Market LLC (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 2.02 Results of Operations and Financial Condition.   On May 22, 2025, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the fourth fiscal quarter and year ended March 31, 2025 and certain corporate updates. A copy of the news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.   In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be de

View on Read The Filing